GLP-1 receptor agonists (e.g. semaglutide) for adults with type 2 diabetes/weight loss – The Neuroendocrine Tumour (NET) Effect
Before you read this… This article is provided to support understanding of how GLP-1 receptor agonists (for example, semaglutide) may relate to type 2 diabetes, weight loss, and neuroendocrine tumours (NETs). It is intended for general education only and is not suggesting that these medicines are suitable or unsuitable for you or anyone else. Every case is different. Only your own specialist team can assess your individual situation and advise on the risks, benefits, and alternatives of GLP-1 receptor agonists or any other treatment in the context of your health and any NET diagnosis. Updated 24 Dec 2025 Novo…